Financial Statement, 1 January – 31 December 2013*
Financial summary for the year as a whole. Continuing Group operations, excluding Cross Pharma. · Net turnover totalled SEK 446.1 million (SEK 170.6 m), SEK 258.5 (4.4) million of which represented non-recurrent payments. · The profit/loss after tax was SEK 16.0 million (SEK -234.1 m). · Basic and diluted earnings per share totalled SEK 0.51 (SEK -7.49). · The cash flow from operating activities amounted to SEK 43.0 million (SEK -139.5 m), while liquid assets and short-term investments totalled SEK 402.2 million (SEK 296.7 m) at the period end. Q4 2013 (October - December).